Emedastine Difumarate
Click to View Image
C17H26N4O·2C4H4O4 534.57
1H-Benzimidazole,1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-,(E)-2-butenedioate (1:2).
1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole fumarate (1:2) [87233-62-3].
»Emedastine Difumarate contains not less than 98.5percent and not more than 101.0percent of C17H26N4O·2C4H4O4,calculated on the dried basis.
Packaging and storage— Preserve in tight,light-resistant containers,at controlled room temperature.
USP Reference standards á11ñ USP Emedastine Difumarate RS.
Identification—
A:Infrared Absorption á197Kñ
Test specimen— Dry for 3hours at 105.
B: The retention time of the major peak in the chromatogram of the Test solutioncorresponds to that of emedastine in the chromatogram of the System suitability solution,as obtained from the Chromatographic puritytest.
C: Dissolve about 23mg of Emedastine Difumarate in 25mLof water.Add 1mLof a solution prepared by mixing 20mLof cupric sulfate solution (1in 5)and 8mLof pyridine:a precipitate is formed in the blue solution within one minute.
pHá791ñ: between 3.0and 4.5,in a solution (2in 1000).
Loss on drying á731ñ Dry at 105for 3hours:it loses not more than 0.5%of its weight.
Residue on ignition á281ñ: not more than 0.1%.
Heavy metals,Method IIá231ñ: not more than 0.002%.
Chromatographic purity—
Buffer solution— Dissolve 3.9g of monobasic sodium phosphate and 2.5g of sodium dodecyl sulfate in 1.0liter of water.Adjust with phosphoric acid to a pHof 2.4.
Mobile phase— Prepare a filtered and degassed mixture of Buffer solutionand acetonitrile (1:1).Make adjustments if necessary (see System Suitabilityunder Chromatography á621ñ).
System suitability solution— Prepare a solution in Mobile phasecontaining 0.10mg of USP Emedastine Difumarate RSand 0.04mg of 4-methylbenzophenone per mL.
Standard solution— Dissolve an accurately weighed quantity of USP Emedastine Difumarate RSin Mobile phase,and dilute,stepwise if necessary,with Mobile phaseto obtain a solution having a known concentration of about 0.003mg per mL.
Test solution— Prepare a solution of Emedastine Difumarate in Mobile phasecontaining about 1.0mg per mL.
Chromatographic system (see Chromatography á621ñ)— The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm ×15-cm column that contains 5-µm packing L1.The flow rate is about 1.0mLper minute.Chromatograph the System suitability solution,and record the peak responses as directed for Procedure:the relative retention times are about 0.2for fumaric acid,1.0for emedastine,and 2.0for 4-methylbenzophenone;the resolution,R,is not less than 2.0;the column efficiency determined from the emedastine peak is not less than 1500theoretical plates;the tailing factor is not more than 2.0;and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 10µL)of the Mobile phase,Standard solution,and Test solutioninto the chromatograph,and record the chromatograms,allowing the elution to continue for a period of not less than twice the retention time of emedastine.Measure the areas for all of the peaks,disregarding the fumaric acid peak and peaks corresponding to those obtained from the Mobile phase.Calculate the percentage of each impurity in the portion of Emedastine Difumarate taken by the formula:
100(ri/rS),
in which riis the peak response for each impurity obtained from the Test solution;and rSis the peak response for emedastine in the Standard solution:not more than 0.3%of any individual impurity is found;and not more than 1.0%of total impurities is found.
Assay— Dissolve about 200mg of Emedastine Difumarate,accurately weighed,in 50.0mLof glacial acetic acid.Titrate with 0.1Nperchloric acid VS,determining the endpoint potentiometrically,using suitable electrodes (see Titrimetry á541ñ).Perform a blank determination,and make any necessary correction.Each mLof 0.1Nperchloric acid is equivalent to 26.73mg of C17H26N4O·2C4H4O4.
Auxiliary Information— Staff Liaison:Karen A Russo,Ph.D.,Scientist
Expert Committee:(PA1)Pharmaceutical Analysis 1
USP28–NF23Page 728
Pharmacopeial Forum:Volume No.28(4)Page 1110
Phone Number:1-301-816-8379